MONTE ROSA THERAPEUTICS INC (GLUE) — insider trading
Health Care · NASDAQ
MONTE ROSA THERAPEUTICS INC (GLUE) has 62 reported SEC Form 4 insider transactions in our data, including 22 open-market sales among the most recent 62 (latest 2026-10-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | Officer (Principal Accounting Officer) | Open-market sale | 13 | $10.56 | $137 | Form 4 |
| 2026-07-16 | Warmuth Markus | Director, Officer (President & CEO) | Open-market sale | 9,500 | $23.18 | $220.2K | Form 4 |
| 2026-07-15 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 4,351 | — | $0 | Form 4 |
| 2026-07-15 | Champoux Jennifer | Officer (Chief Operating Officer) | Open-market sale | 4,351 | $23.38 | $101.7K | Form 4 |
| 2026-07-15 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion | 4,351 | $3.98 | $17.3K | Form 4 |
| 2026-07-06 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-07-06 | Townson Sharon | Officer (Chief Scientific Officer) | Open-market sale | 400 | $24.13 | $9.7K | Form 4 |
| 2026-07-06 | Townson Sharon | Officer (Chief Scientific Officer) | Open-market sale | 5,600 | $23.25 | $130.2K | Form 4 |
| 2026-07-06 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion | 6,000 | $6.14 | $36.8K | Form 4 |
| 2026-07-01 | Behbahani Ali | Director | Other acquisition or disposition | 15,000 | — | $0 | Form 4 |
| 2026-07-01 | Behbahani Ali | Director | Other acquisition or disposition | 15,000 | — | $0 | Form 4 |
| 2026-07-01 | Behbahani Ali | Director | Other acquisition or disposition | 1,000,000 | — | $0 | Form 4 |
| 2026-06-30 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 5,407 | — | $0 | Form 4 |
| 2026-06-30 | Janku Filip | Officer (Chief Medical Officer) | Open-market sale | 5,407 | $24.50 | $132.5K | Form 4 |
| 2026-06-30 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion | 5,407 | $13.41 | $72.5K | Form 4 |
| 2026-06-29 | Manning Anthony M. | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-29 | Manning Anthony M. | Director | Open-market sale | 10,000 | $23.11 | $231.1K | Form 4 |
| 2026-06-29 | Manning Anthony M. | Director | Option exercise / conversion | 10,000 | $4.16 | $41.6K | Form 4 |
| 2026-06-29 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-06-29 | Janku Filip | Officer (Chief Medical Officer) | Open-market sale | 6,000 | $22.95 | $137.7K | Form 4 |
| 2026-06-29 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion | 6,000 | $7.56 | $45.4K | Form 4 |
| 2026-06-24 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-24 | Janku Filip | Officer (Chief Medical Officer) | Open-market sale | 30,000 | $21.42 | $642.7K | Form 4 |
| 2026-06-24 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion | 30,000 | $7.56 | $226.8K | Form 4 |
| 2026-06-23 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-23 | Townson Sharon | Officer (Chief Scientific Officer) | Open-market sale | 3,000 | $20.00 | $60.0K | Form 4 |
| 2026-06-23 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion | 3,000 | $6.14 | $18.4K | Form 4 |
| 2026-06-23 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,175 | — | $0 | Form 4 |
| 2026-06-23 | Champoux Jennifer | Officer (Chief Operating Officer) | Open-market sale | 2,175 | $20.00 | $43.5K | Form 4 |
| 2026-06-23 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion | 2,175 | $3.98 | $8.7K | Form 4 |
| 2026-06-23 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-06-23 | Janku Filip | Officer (Chief Medical Officer) | Open-market sale | 11,845 | $20.22 | $239.5K | Form 4 |
| 2026-06-23 | Janku Filip | Officer (Chief Medical Officer) | Option exercise / conversion | 6,000 | $7.56 | $45.4K | Form 4 |
| 2026-06-17 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-17 | Townson Sharon | Officer (Chief Scientific Officer) | Open-market sale | 3,000 | $19.00 | $57.0K | Form 4 |
| 2026-06-17 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion | 3,000 | $6.14 | $18.4K | Form 4 |
| 2026-06-17 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,176 | — | $0 | Form 4 |
| 2026-06-17 | Champoux Jennifer | Officer (Chief Operating Officer) | Open-market sale | 2,176 | $19.00 | $41.3K | Form 4 |
| 2026-06-17 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion | 2,176 | $3.98 | $8.7K | Form 4 |
| 2026-06-11 | Siu Christine | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | Hughes Eric A | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | Blackwell Kimberly | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | Skvarka Jan | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | Manning Anthony M. | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | SCHIFF ANDREW N | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-11 | Behbahani Ali | Director | Grant / award / vesting (derivative) | 25,800 | — | $0 | Form 4 |
| 2026-06-01 | Warmuth Markus | Director, Officer (President & CEO) | Open-market sale | 468 | $19.73 | $9.2K | Form 4 |
| 2026-06-01 | Warmuth Markus | Director, Officer (President & CEO) | Open-market sale | 4,998 | $19.41 | $97.0K | Form 4 |
| 2026-05-29 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-05-29 | Townson Sharon | Officer (Chief Scientific Officer) | Open-market sale | 6,000 | $19.87 | $119.2K | Form 4 |
| 2026-05-29 | Townson Sharon | Officer (Chief Scientific Officer) | Option exercise / conversion | 6,000 | $6.14 | $36.8K | Form 4 |
| 2026-05-27 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,175 | — | $0 | Form 4 |
| 2026-05-27 | Champoux Jennifer | Officer (Chief Operating Officer) | Open-market sale | 2,175 | $20.00 | $43.5K | Form 4 |
| 2026-05-27 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion | 2,175 | $3.98 | $8.7K | Form 4 |
| 2026-05-22 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,176 | — | $0 | Form 4 |
| 2026-05-22 | Champoux Jennifer | Officer (Chief Operating Officer) | Open-market sale | 2,176 | $19.00 | $41.3K | Form 4 |
| 2026-05-22 | Champoux Jennifer | Officer (Chief Operating Officer) | Option exercise / conversion | 2,176 | $3.98 | $8.7K | Form 4 |
| 2026-05-21 | Manning Anthony M. | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-05-21 | Manning Anthony M. | Director | Open-market sale | 10,000 | $18.01 | $180.1K | Form 4 |
| 2026-05-21 | Manning Anthony M. | Director | Option exercise / conversion | 10,000 | $4.16 | $41.6K | Form 4 |
| 2026-05-01 | Warmuth Markus | Director, Officer (President & CEO) | Open-market sale | 5,467 | $18.92 | $103.4K | Form 4 |
| 2026-04-14 | Warmuth Markus | Director, Officer (President & CEO) | Open-market sale | 8,000 | $17.64 | $141.1K | Form 4 |
Ask the chat about GLUE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MONTE ROSA THERAPEUTICS INC (GLUE).
Last updated 2026-10-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.